Quarterly report pursuant to Section 13 or 15(d)

Statement of Operations

v2.4.0.8
Statement of Operations (USD $)
 3 Months Ended 156 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Mar. 31, 2014
Revenues:      
Research $ 0 $ 0 $ 0
Expenses:      
General and administrative 1,413,456 1,210,752 35,733,963
Research and development 1,271,574 552,466 39,803,212
Patent fees 72,020 136,491 3,032,327
Depreciation and amortization 9,044 9,316 729,100
Total Expenses 2,766,094 1,909,025 79,298,602
Loss from Operations (2,766,094) (1,909,025) (79,298,602)
Other Income (Expense)      
Realized loss on marketable securities     (13,301)
Interest income 32,291 10,018 1,523,970
Interest expense     (301,147)
Other income     56,047
Unrealized (loss)/gain on fair value of warrants (11,660,524) 368,902 (8,686,197)
Unrealized gain on fair value of put feature on common stock     2,315,539
Financing expense (206,172)   (1,382,515)
Beneficial conversion feature     (1,625,000)
Total Other Income (Expense) (11,834,405) 378,920 (8,112,604)
Loss Before Provision for Income Taxes (14,600,499) (1,530,105) (87,411,206)
Provision for Income Taxes 0 0 0
Net Loss $ (14,600,499) $ (1,530,105) $ (87,411,206)
Net loss per share, basic and diluted $ (0.09) $ (0.01)  
Weighted average number of shares outstanding, basic and diluted 170,112,570 119,428,989